17 completed, 13 unknown, 4 not yet recruiting, 2 recruiting. 12 Not applicable, 10 Phase 2, 10 Phase 3, 4 Phase 1, 3 Phase 4.
Follow Vitreoretinopathy, Proliferative: new trials by email Literature Review of Vitreoretinopathy, Proliferative trials Research Report on Vitreoretinopathy, Proliferative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy Topotecan - Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 50 | 2026-12-01 | 2026-10-16 |
| Imaging and Predictive Modelling of Proliferative Vitreoretinopathy. Proliferative Vitreoretinopathy | Enrolling by invitation | University College, London | 100 | 2026-10-12 | 2026-07-02 | |
| Comparison of Visual Outcomes of Pars Plana Vitrectomy With and Without Injection Clexane for Rhegmatogenous Retinal Detachment Proliferative Vitreoretinopathy Enoxaparin Sodium, Pars Plana Vitrectomy - Rhegmatogenous Retinal Detachment With Grade C Proliferative Vitreoretinopathy | Not applicable | Active not recruiting | Lahore General Hospital | 60 | 2026-05-01 | 2026-08-26 |
| Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy | Not yet recruiting | University College, London | 50 | 2026-04-27 | 2026-05-06 | |
| Intravitreal Triamcinolone and Biomarkers in Rhegmatogenous Retinal Detachment Standard Vitrectomy, Triamcinolone acetonide (TA) - Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment | Not applicable | Completed | Anggun Rama Yudantha | 60 | 2025-05-06 | 2026-08-19 |
| Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment Intravitreal topotecan, Retinal detachment surgery - Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy | Phase 2 | Not yet recruiting | Unity Health Toronto | 394 | 2025-03-01 | 2025-03-06 |
| Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment Netarsudil Ophthalmic - Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 1 / Phase 2 | Recruiting | Massachusetts Eye and Ear Infirmary | 48 | 2025-01-14 | 2026-10-16 |
| Methotrexate in Retinal Detachment With Proliferative Vitreoretinopathy parsplana vitrectomy, adjunctive use of Methotrexate - Retinal Detachment | Not applicable | Completed | Benha University | 20 | 2024-06-09 | 2025-07-10 |
| "Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy" Methotrexate - Proliferative Vitreoretinopathy | Phase 1 / Phase 2 | Unknown | University of Health Sciences Lahore | 120 | 2024-03-01 | 2024-03-01 |
| Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial Methotrexate Injection, Methotrexate Infusion, Sham Injection - Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment | Phase 2 | Unknown | Cincinnati Eye Institute, Southwest Ohio | 860 | 2024-03-01 | 2024-09-19 |
| REtinal Detachment Outcomes Study Pars plana vitrectomy, Pars plana vitrectomy with scleral buckle, Sulfur hexafluoride gas tamponade - Retinal Detachment | Not applicable | Recruiting | CHU de Quebec-Universite Laval | 560 | 2023-09-26 | 2023-11-18 |
| A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud - Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 2 / Phase 3 | Unknown | Wills Eye | 80 | 2023-02-06 | 2024-07-30 |
| Outcomes of Retinal Re-surgeries in Silicone Oil Filled Eyes Resurgery In Silicone Oil Filled Eyes - Retinal Detachment, Proliferative Vitreo-Retinopathy | Completed | Ahalia Foundation Eye Hospital | 33 | 2023-01-01 | 2024-09-25 | |
| Air Versus Gas Tamponade in Primary Retinal Detachment Pars plana vitrectomy - Retinal Detachment, Proliferative Vitreoretinopathy | Not applicable | Unknown | Benha University | 40 | 2022-09-26 | 2022-09-30 |
| Internal Limiting Membrane Peeling in Retinal Detachment Surgery Control group, Intervention group - Retinal Detachment, Proliferative Vitreoretinopathy | Not applicable | Not yet recruiting | Central Hospital, Nancy, France | 126 | 2022-09-01 | 2022-09-13 |
| Ozurdex in Reducing PVR After Vitreotomy in PDR slow-release dexamethasone implant - Diabetic Retinopathy | Not applicable | Unknown | Peking University People's Hospital | 30 | 2022-06-15 | 2022-06-13 |
| Retinal Redetachment After Silicone Oil Removal : a Risk Factor Analysis no intervention - Retinal Redetachment After Silicone Oil Removal | Completed | Central Hospital, Nancy, France | 307 | 2022-05-05 | 2022-12-13 | |
| Intravitreal Infliximab for Proliferative Vitreoretinopathy Intravitreal infliximab, Pars plana vitrectomy - Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 2 | Completed | Cairo University | 66 | 2021-11-26 | 2024-01-19 |
| Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment Intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml), Placebo - Retinal Detachment, Proliferative Vitreoretinopathy | Not applicable | Completed | Alexandria University | 42 | 2021-10-21 | 2023-12-19 |
| Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy Nepafenac 0.1% eyedrops, Control (placebo) group - Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment | Phase 4 | Completed | Universitas Indonesia | 61 | 2021-04-28 | 2025-09-09 |
Showing 20 of 40. Sign in to see all of them.
Retinal Detachment (19) · Diabetic Retinopathy (3) · Camurati-Engelmann Syndrome (1) · Epiretinal Membrane (1) · Glaucoma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Pain, Postoperative (1) · Pterygium (1) · Retinal Perforations (1) · Retinoschisis (1)
Eye Diseases (40) · Retinal Diseases (40) · Cardiovascular Diseases (3) · Diabetes Complications (3) · Diabetes Mellitus (3) · Diabetic Angiopathies (3) · Endocrine System Diseases (3) · Vascular Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Congenital Abnormalities (1) · Conjunctival Diseases (1) · Heredodegenerative Disorders, Nervous System (1)
Methotrexate (4) · Heparin, Low-Molecular-Weight (3) · Scleral Buckling (3) · Triamcinolone Acetonide (3) · Bevacizumab (2) · Colchicine (2) · Fluorouracil (2) · Ophthalmic Solutions (2) · Topotecan (2) · perflutren (2) · Adrenocorticotropic Hormone (1) · Antimetabolites (1) · Bupivacaine (1) · Control Groups (1) · Dexamethasone (1)
Shahid Beheshti University of Medical Sciences (6) · Wills Eye (3) · Benha University (2) · Central Hospital, Nancy, France (2) · Massachusetts Eye and Ear Infirmary (2) · University College, London (2) · Ahalia Foundation Eye Hospital (1) · Aldeyra Therapeutics, Inc. (1) · Alexandria University (1) · Anggun Rama Yudantha (1) · Asociación para Evitar la Ceguera en México (1) · CHU de Quebec-Universite Laval (1) · Cairo University (1) · Centro Oftalmológico Dr Charles (1) · Cincinnati Eye Institute, Southwest Ohio (1)
United States (12) · Iran (6) · Egypt (4) · Canada (2) · Indonesia (2) · Pakistan (2) · United Kingdom (2) · Argentina (1) · China (1) · France (1) · India (1) · Mexico (1)
Hamid Ahmadieh, MD (5) · Jason Hsu, MD (3) · Leo Kim, MD, PhD (2) · Ahmad Al-Moujahed, MD, PhD, MPH (1) · Ahmad Fauzan (1) · Ahmad Z Jamil, FCPS,FRCS (1) · Ahmed A Abdel-Kader, MD, PhD (1) · Ahmed A Abdelshafy, MD (1) · Ahmed M Abdelbaki, MD, PhD (1) · Ahmed M Younes, MD, MSc (1) · Ali Dirani, MD MSc MPH (1) · Anggun Rama Yudantha, Sp.M(K) (1) · Ari Djatikusumo, MD (1) · Ayman G Elnahry, MD, PhD (1) · C R Asla Jahan, DNB (1)
PMID 32408387, PMID 29621507, PMID 12644944, PMID 16829804, PMID 19107502, PMID 20182404, PMID 29282562, PMID 29299741, PMID 30024983, PMID 30451176, PMID 30451186, PMID 31126280, PMID 31744475, PMID 34336257, PMID 34462712, PMID 38124155, PMID 38433191, PMID 39148018, PMID 39572739, PMID 42568743, PMID 7488586